Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Santhera Pharmaceuticals Holding AG    SANN   CH0027148649

SANTHERA PHARMACEUTICALS HOLDING AG

(SANN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Santhera Pharmaceuticals : Completes Capital Increase for Financing Arrangements

10/22/2020 | 01:10am EST

Santhera Pharmaceuticals Holding AG

Hohenrainstrasse 24, 4133 Pratteln, Switzerland

Phone: +41 61 906 89 50 | Fax: +41 61 906 89 51

www.santhera.com

Santhera Completes Capital Increase for Financing Arrangements

Pratteln, Switzerland, October 22, 2020 - Santhera Pharmaceuticals (SIX: SANN) announces that it has issued 1,011,363 reserve shares. The number of shares recorded in the commercial register is now 16,270,000 shares.

On October 21, 2020, 1,011,363 shares were issued out of the existing authorized capital as treasury shares. Santhera expects to use these shares for its financing arrangements and/or for general financing purposes. The new shares will be listed as per October 22, 2020.

About Santhera

Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare neuromuscular and pulmonary diseases with high unmet medical need. Santhera has an exclusive license for all indications worldwide to vamorolone, a first-in-class dissociative steroid with novel mode of action, currently investigated in a pivotal study in patients with DMD as an alternative to standard corticosteroids. The clinical stage pipeline also includes lonodelestat (POL6014) to treat cystic fibrosis (CF) and other neutrophilic pulmonary diseases as well as an exploratory gene therapy approach targeting congenital muscular dystrophies. Santhera out-licensedex-North American rights to its first approved product, Raxone® (idebenone), for the treatment of Leber's hereditary optic neuropathy (LHON) to Chiesi Group. For further information, please visit www.santhera.com.

Raxone® is a trademark of Santhera Pharmaceuticals.

For further information please contact: public-relations@santhera.comor

Eva Kalias, Head External Communications Phone: +41 79 875 27 80 eva.kalias@santhera.com

Disclaimer / Forward-looking statements

This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Santhera Pharmaceuticals Holding AG. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.

# # #

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Santhera Pharmaceuticals Holding AG published this content on 22 October 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 October 2020 05:09:06 UTC


© Publicnow 2020
All news about SANTHERA PHARMACEUTICALS HOLDING AG
11/26SANTHERA PHARMACEUTICALS : Completes Capital Increase for Financing Arrangements
AQ
11/25SANTHERA PHARMACEUTICALS : Completes Capital Increase for Financing Arrangements
PU
11/25SANTHERA PHARMACEUTICALS : Completes Capital Increase for Financing Arrangements
AQ
11/25SANTHERA PHARMACEUTICALS : Completes Capital Increase for Financing Arrangements
AQ
11/25Santhera Completes Capital Increase for Financing Arrangements
GL
11/17SANTHERA PHARMACEUTICALS : ReveraGen Receives $3.3 Million NIH Commercialization..
PU
11/17SANTHERA PHARMACEUTICALS : ReveraGen Receives $3.3 Million NIH Commercialization..
PU
11/17SANTHERA PHARMACEUTICALS : ReveraGen Receives $3.3 Million NIH Commercialization..
AQ
11/10SANTHERA PHARMACEUTICALS : to Present at Jefferies Virtual London Healthcare Con..
PU
11/10SANTHERA PHARMACEUTICALS : to Present at Jefferies Virtual London Healthcare Con..
AQ
More news
Financials
Sales 2020 14,6 M 16,3 M 16,3 M
Net income 2020 -55,3 M -61,7 M -61,7 M
Net Debt 2020 - - -
P/E ratio 2020 -0,94x
Yield 2020 -
Capitalization 53,9 M 60,2 M 60,1 M
Capi. / Sales 2020 3,69x
EV / Sales 2021 1,92x
Nbr of Employees 113
Free-Float 86,1%
Chart SANTHERA PHARMACEUTICALS HOLDING AG
Duration : Period :
Santhera Pharmaceuticals Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANTHERA PHARMACEUTICALS HOLDING AG
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 2
Average target price 3,00 CHF
Last Close Price 2,99 CHF
Spread / Highest target 0,33%
Spread / Average Target 0,33%
Spread / Lowest Target 0,33%
EPS Revisions
Managers
NameTitle
Dario Eklund Chief Executive Officer
Elmar J. Schnee Chairman
Andrew P. Smith Chief Financial Officer
Kristina Sjöblom Nygren Chief Medical Officer, EVP & Head-Development
Thomas Meier Director
Sector and Competitors